2015
Antifibrotic Therapies in the Liver
Mehal W, Schuppan D. Antifibrotic Therapies in the Liver. Seminars In Liver Disease 2015, 35: 184-198. PMID: 25974903, PMCID: PMC5743222, DOI: 10.1055/s-0035-1550055.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsCell- and Tissue-Based TherapyDisease ProgressionHumansLiver CirrhosisConceptsAntifibrotic therapyIdeal patient populationRegression of fibrosisBest noninvasive methodFibrolytic propertiesDose titrationClinical outcomesFibrosis regressionPulmonary fibrosisPatient populationCombination therapyLiver fibrosisIndividualized therapyEncouraging dataFibrotic responseTherapeutic targetDrug AdministrationFibrosisTherapyNoninvasive methodInterindividual heterogeneityCell populationsAntifibroticsLiverFibrolysis
2010
Cell Death and Fibrogenesis
Mehal W, Imaeda A. Cell Death and Fibrogenesis. Seminars In Liver Disease 2010, 30: 226-231. PMID: 20665375, PMCID: PMC3219753, DOI: 10.1055/s-0030-1255352.BooksConceptsHepatic stellate cellsQuiescent hepatic stellate cellsChronic liver injuryNatural killer cellsCell deathHIV infectionLiver injuryNK cellsKiller cellsAntifibrotic effectsImmune suppressionImmune cellsProfibrotic effectsStellate cellsHepatocyte deathHSC apoptosisDeathCellular deathFibrosisCellular debrisMatrix depositionHSC deathSurvival signalsApoptotic bodiesProapoptotic signals